-
Product Insights
New![]()
Net Present Value Model: Annexon Inc’s ANX-005
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Annexon Inc’s ANX-007
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-009 in Lupus Nephritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANX-009 in Lupus Nephritis Drug Details:ANX-009 is under development for the treatment of lupus nephritis. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-1502 in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANX-1502 in Autoimmune Disorders Drug Details:ANX-1502 is under development for the treatment of chronic autoimmune, multifocal motor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-105 in Neurodegenerative Diseases
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANX-105 in Neurodegenerative Diseases Drug Details:ANX-105 is under development for the treatment of chronic autoimmune and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-105 in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ANX-105 in Autoimmune Disorders Drug Details:ANX-105 is under development for the treatment of chronic autoimmune and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Huntington Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Huntington Disease Drug Details: ANX-005 is under development for the treatment and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-007 in Geographic Atrophy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANX-007 in Geographic Atrophy Drug Details: ANX-007 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Amyotrophic Lateral Sclerosis Drug Details: ANX-005 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Acquired (Autoimmune) Hemolytic Anemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Acquired (Autoimmune) Hemolytic Anemia Drug Details: ANX-005 is under development for the...
-
Product Insights
New![]()
Net Present Value Model: CRISPR Therapeutics AG’s CTX-120
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: iTeos Therapeutics Inc’s Belrestotug
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ruzasvir in Hepatitis C
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ruzasvir in Hepatitis C Drug Details: Ruzasvir is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-282 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-282 in Inflammation Drug Details:EP-282 is under development for the treatment of intestinal infection, unspecified cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GSK-3206641A in Influenza A Virus, H7N9 Subtype Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GSK-3206641A in Influenza A Virus, H7N9 Subtype InfectionsDrug Details:GSK-3206641A is under development for the prevention of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Labafenogene marselecobac in Phenylketonuria (PKU)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Labafenogene marselecobac in Phenylketonuria (PKU) Drug Details: Labafenogene marselecobac is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EVX-02 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EVX-02 in MelanomaDrug Details:EVX-02Â is under development for the treatment of resected melanoma. The drug candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RX-108 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RX-108 in Solid TumorDrug Details:RX-108 is under development for the treatment of primary hepatocellular carcinoma, locally...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Transcon Tlr7/8 Agonist in Squamous Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ACP-017 in Squamous Cell Carcinoma Drug Details: Small molecule is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTD-1801 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HTD-1801 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details:HTD-1801 (berberine ursodeoxycholate) is under development for...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.